Niagen Bioscience Inc. (NAGE)
NASDAQ (CM) NASDAQ (CM) Primary 
Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program Transcript
Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program Transcript
Implied Volatility Surging for Niagen Bioscience Stock Options
Investors need to pay close attention to NAGE stock based on the movements in the options market lately.
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates
Niagen Bioscience (NAGE) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.04 per share a year ago.
Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript
Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript
Niagen: High-Quality Growth At A Fair Price
Niagen's fiscal 2025 revenue growth and profitability improvement can make the stock attractive for growth-focussed investors. The company's low debt levels and relatively high amount of cash on hand allow them financial flexibility, even during market distress. Macroeconomic headwinds exist, especially low consumer confidence and high energy prices, but share issuance also poses a threat to existing shareholders.
Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates
Niagen Bioscience (NAGE) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.03 per share a year ago.
Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates
Niagen Bioscience (NAGE) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.02 per share a year ago.
Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript
Niagen Bioscience, Inc. ( NAGE ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Kendall Knysch - Head of Media Relations & Partnerships Robert Fried - CEO & Director Ozan Pamir - CFO & Principal Accounting Officer Conference Call Participants Destiny Buch - Ladenburg Thalmann & Co. Inc., Research Division Susan Anderson - Canaccord Genuity Corp., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Sean McGowan - ROTH Capital Partners, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by, and welcome to the Niagen Biosciences, Inc. Third Quarter of 2025 Earnings Conference Call.
Niagen Bioscience (NAGE) Reports Next Week: What to Expect
Niagen Bioscience (NAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates
Niagen Bioscience (NAGE) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago.
Niagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic Trends
NAGE is a leader in the growing NAD+ supplement market, benefiting from rising health and longevity trends and strong brand awareness with its flagship Tru Niagen product. Analyst estimates for 2025 remain too low; further upside revisions look possible based on our alternative data channel checks. Our DCF valuation suggests at least 20% upside as a standalone company, and even more if viewed through the lens of a potential acquirer.
Niagen Bioscience: High Conviction, High Expectations
Niagen Bioscience's stock price is breaking out with strong fundamentals, proprietary IP, and a leadership position in the NAD+ longevity market. Revenue and margins are rising, driven by Tru Niagen e-commerce and pharma-grade injectables, with operating leverage and efficient marketing boosting profitability. Valuation is rich, reflecting high expectations for continued growth and clinical pipeline success, but execution risk is elevated at these multiples.
